EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Prediction of First and Recurrent Falls in Parkinson's Disease

Joaquin A. Vizcarra, Kat Hefter, Michael Tran Duong, Ashkan Ertefaie, Umberto Tachinardi, Christopher A. Olm, Hamsanandini Radhakrishnan, Corey T. McMillan, David Irwin, Daniel Weintraub, Brian Litt, Dani S. Bassett, Andrew Siderowf

Annals of Neurology · 2026-10-30

DOI: 10.1002/ana.78400 ↗
AbstractBibliografische Angaben

Abstract

Objective To develop and externally validate prediction models for next‐year falls in Parkinson's disease (PD), and to evaluate the incremental value of imaging and fluid biomarkers. Methods We developed models in Parkinson's Progression Markers Initiative (PPMI) to predict next‐year falls with external validation in University of Pennsylvania (UPenn) cohorts. We evaluated incident falls among visits without current or prior falls and recurrent falls among visits with current falls. We calculated area under the receiver operating characteristic curve (AUROC), area under the precision‐recall curve (AUPRC), and development‐derived risk strata. Results The incident model, comprising Movement Disorder Society–Unified Parkinson's Disease Rating Scale Part III, Montreal Cognitive Assessment, and Geriatric Depression Scale (GDS), was developed in 773 visit‐pairs and validated in 589 visit‐pairs. AUROC was 0.704 (95% confidence interval [CI] = 0.653–0.750) in PPMI and 0.630 (95% CI = 0.564–0.687) in UPenn. Incident fall risk increased from 7.1 to 18.5% across low‐ to high‐risk groups in UPenn. The recurrent model, comprising Hoehn and Yahr (H&Y), GDS, and Symbol Digit Modalities Test, was developed in 302 visit‐pairs and validated in 137 visit‐pairs. AUROC was 0.683 (95% CI = 0.623–0.753) in PPMI and 0.641 (95% CI = 0.538–0.732) in UPenn. Recurrent fall rates increased from 22.2 to 65.0% across low‐ to high‐risk groups in UPenn. Exploratory biomarker augmentation modestly improved discrimination beyond clinical models in PPMI, but not in external validation, where estimates were imprecise. Interpretation Clinical measures may identify next‐year fall risk in PD with moderate discrimination, although performance attenuated in external validation. Exploratory biomarkers provided modest incremental value in development but not in external validation. ANN NEUROL 2026

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →